沃华医药(002107) - 2025 Q4 - 年度业绩预告

Financial Projections - The company expects a net profit of between 80 million and 115 million CNY for the year 2025, representing a year-on-year growth of 119.76% to 215.90%[5] - The net profit after deducting non-recurring gains and losses is projected to be between 75 million and 105 million CNY, indicating a growth of 118.38% to 205.74% compared to the previous year[5] - Basic earnings per share are anticipated to be between 0.1386 and 0.1992 CNY, up from 0.0631 CNY in the same period last year[5] - There are no significant uncertainties affecting the accuracy of the performance forecast as of the announcement date[9] - The forecast data is preliminary and will be finalized in the company's 2025 annual report[10] Management Strategy - The company has implemented a detailed management strategy focusing on cost reduction and sales increase, which has effectively controlled costs[7] Market Development - Marketing reforms have strengthened the sales team, adapting to market competition post-collection for the company's product, leading to a trend of price-for-volume[8] - The hospital market has been consolidated and developed, with a successful extension into the outpatient market, creating a coordinated development model[8]